Please assess the completion status of the following clinical trial:

Trial Title: Sublingual Immunotherapy In Alternaria-Induced Rhinitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Allergic rhinitis~* Symptoms May-October~* Specific IgE to alternaria (skin test/radioallergosorbent \[RAST\] test)~* Age \>14~Exclusion Criteria:~* Sensitization to mites, parietaria, mugwort~* Pregnancy-lactation~* Malignancies~* Chronic systemic steroids~* Previous immunotherapy to alternaria

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- SLIT (Type: EXPERIMENTAL): sublingual immunotherapy biologically standardized
- placebo (Type: PLACEBO_COMPARATOR): same preparation of SLIT without the allergen

Based on this trial design, predict the completion outcome and termination type (if applicable).